Cargando…

Pharmacological hypothesis: A recombinant probiotic for taming bacterial β‐glucuronidase in drug‐induced enteropathy

Advances in pharmacomicrobiomics have shed light on the pathophysiology of drug‐induced enteropathy associated with the therapeutic use of certain non‐steroidal anti‐inflammatory drugs, anticancer chemotherapies and immunosuppressants. The toxicity pathway results from the post‐glucuronidation relea...

Descripción completa

Detalles Bibliográficos
Autores principales: Jardou, Manon, Brossier, Clarisse, Guiyedi, Kenza, Faucher, Quentin, Lawson, Roland
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9460963/
https://www.ncbi.nlm.nih.gov/pubmed/36082825
http://dx.doi.org/10.1002/prp2.998
_version_ 1784786870878601216
author Jardou, Manon
Brossier, Clarisse
Guiyedi, Kenza
Faucher, Quentin
Lawson, Roland
author_facet Jardou, Manon
Brossier, Clarisse
Guiyedi, Kenza
Faucher, Quentin
Lawson, Roland
author_sort Jardou, Manon
collection PubMed
description Advances in pharmacomicrobiomics have shed light on the pathophysiology of drug‐induced enteropathy associated with the therapeutic use of certain non‐steroidal anti‐inflammatory drugs, anticancer chemotherapies and immunosuppressants. The toxicity pathway results from the post‐glucuronidation release and digestive accumulation of an aglycone generated in the context of intestinal dysbiosis characterized by the expansion of β‐glucuronidase‐expressing bacteria. The active aglycone could trigger direct or indirect inflammatory signaling on the gut epithelium. Therefore, taming bacterial β‐glucuronidase (GUS) activity is a druggable target for preventing drug‐induced enteropathy. In face of the limitations of antibiotic strategies that can worsen intestinal dysbiosis and impair immune functions, we hereby propose the use of a recombinant probiotic capable of mimicking repressive conditions of GUS through an inducible plasmid vector.
format Online
Article
Text
id pubmed-9460963
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-94609632022-09-28 Pharmacological hypothesis: A recombinant probiotic for taming bacterial β‐glucuronidase in drug‐induced enteropathy Jardou, Manon Brossier, Clarisse Guiyedi, Kenza Faucher, Quentin Lawson, Roland Pharmacol Res Perspect Original Articles Advances in pharmacomicrobiomics have shed light on the pathophysiology of drug‐induced enteropathy associated with the therapeutic use of certain non‐steroidal anti‐inflammatory drugs, anticancer chemotherapies and immunosuppressants. The toxicity pathway results from the post‐glucuronidation release and digestive accumulation of an aglycone generated in the context of intestinal dysbiosis characterized by the expansion of β‐glucuronidase‐expressing bacteria. The active aglycone could trigger direct or indirect inflammatory signaling on the gut epithelium. Therefore, taming bacterial β‐glucuronidase (GUS) activity is a druggable target for preventing drug‐induced enteropathy. In face of the limitations of antibiotic strategies that can worsen intestinal dysbiosis and impair immune functions, we hereby propose the use of a recombinant probiotic capable of mimicking repressive conditions of GUS through an inducible plasmid vector. John Wiley and Sons Inc. 2022-09-09 /pmc/articles/PMC9460963/ /pubmed/36082825 http://dx.doi.org/10.1002/prp2.998 Text en © 2022 The Authors. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Jardou, Manon
Brossier, Clarisse
Guiyedi, Kenza
Faucher, Quentin
Lawson, Roland
Pharmacological hypothesis: A recombinant probiotic for taming bacterial β‐glucuronidase in drug‐induced enteropathy
title Pharmacological hypothesis: A recombinant probiotic for taming bacterial β‐glucuronidase in drug‐induced enteropathy
title_full Pharmacological hypothesis: A recombinant probiotic for taming bacterial β‐glucuronidase in drug‐induced enteropathy
title_fullStr Pharmacological hypothesis: A recombinant probiotic for taming bacterial β‐glucuronidase in drug‐induced enteropathy
title_full_unstemmed Pharmacological hypothesis: A recombinant probiotic for taming bacterial β‐glucuronidase in drug‐induced enteropathy
title_short Pharmacological hypothesis: A recombinant probiotic for taming bacterial β‐glucuronidase in drug‐induced enteropathy
title_sort pharmacological hypothesis: a recombinant probiotic for taming bacterial β‐glucuronidase in drug‐induced enteropathy
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9460963/
https://www.ncbi.nlm.nih.gov/pubmed/36082825
http://dx.doi.org/10.1002/prp2.998
work_keys_str_mv AT jardoumanon pharmacologicalhypothesisarecombinantprobioticfortamingbacterialbglucuronidaseindruginducedenteropathy
AT brossierclarisse pharmacologicalhypothesisarecombinantprobioticfortamingbacterialbglucuronidaseindruginducedenteropathy
AT guiyedikenza pharmacologicalhypothesisarecombinantprobioticfortamingbacterialbglucuronidaseindruginducedenteropathy
AT faucherquentin pharmacologicalhypothesisarecombinantprobioticfortamingbacterialbglucuronidaseindruginducedenteropathy
AT lawsonroland pharmacologicalhypothesisarecombinantprobioticfortamingbacterialbglucuronidaseindruginducedenteropathy